Summit Therapeutics vs. Merck: Prepping for a big lung cancer study reveal

Taking stock of the drug industry, from the lab to the medicine chest

September 5, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Andy Wong/AP STAT+ | Summit Therapeutics vs. Merck: Prepping for a big lung cancer study reveal The upcoming HARMONi-2 presentation at the World Conference on Lung Cancer should indicate whether Summit's drug can chip away at the dominance of Keytruda. By Adam Feuerstein STAT+ | Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target Novo Nordisk and Eli Lilly, makers of blockbuster GLP-1 drugs, test amylin hormone receptor treatments in pursuit of fewer side effects. By Elaine Chen and Allison DeAngelis STAT+ | Vor Biopharma's 'shielded' transplant delays relapse in leukemia patients Eight of 10 patients with high-risk acute myeloid leukemia remain in remission after receiving a transplant, followed by maintenance treatment. By Adam Feuerstein Molly Ferguson/STAT STAT+ | Alnylam versus BridgeBio: The ATTR-CM debate Alnylam Pharmaceuticals executives instigated a dustup when they asserted a cardiologist made mistakes during a discussion about its heart treatment. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser